Victory Capital Management
AKBA icon

Victory Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Victory Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.4K Sell
30,170
-99,000
-77% -$118K ﹤0.01% 2417
2026
Q1 		$180K Sell
129,170
-121,367
-48% -$167K ﹤0.01% 2209
2025
Q4 		$403K Sell
250,537
-35,848
-13% -$75.1K ﹤0.01% 2071
2025
Q3 		$782K Buy
286,385
+256,353
+854% +$853K ﹤0.01% 1953
2025
Q2 		$109K Buy
30,032
+4,768
+19% +$13.1K ﹤0.01% 2318
2025
Q1 		$48.5K Sell
25,264
-417
-2% -$851 ﹤0.01% 2367
2024
Q4 		$48.8K Buy
25,681
+336
+1% +$583 ﹤0.01% 2399
2024
Q3 		$33.5K Buy
25,345
+518
+2% +$692 ﹤0.01% 2419
2024
Q2 		$25.3K Buy
24,827
+3,010
+14% +$3.72K ﹤0.01% 2412
2024
Q1 		$39.9K Sell
21,817
-702
-3% -$1.12K ﹤0.01% 2393
2023
Q4 		$27.9K Sell
22,519
-732,969
-97% -$748K ﹤0.01% 2485
2023
Q3 		$861K Buy
755,488
+93,590
+14% +$120K ﹤0.01% 1732
2023
Q2 		$606K Buy
661,898
+404,154
+157% +$390K ﹤0.01% 1902
2023
Q1 		$144K Buy
257,744
+237,922
+1,200% +$182K ﹤0.01% 2305
2022
Q4 		$11.4K Sell
19,822
-8
-0% -$3 ﹤0.01% 2539
2022
Q3 		$6K Sell
19,830
-4,148
-17% -$1.63K ﹤0.01% 2675
2022
Q2 		$8K Buy
23,978
+965
+4% +$405 ﹤0.01% 2663
2022
Q1 		$10K Sell
23,013
-657
-3% -$1.41K ﹤0.01% 2679
2021
Q4 		$53K Sell
23,670
-677
-3% -$1.85K ﹤0.01% 2636
2021
Q3 		$70K Buy
24,347
+883
+4% +$2.52K ﹤0.01% 2658
2021
Q2 		$89K Buy
23,464
+276
+1% +$929 ﹤0.01% 2611
2021
Q1 		$78K Buy
23,188
+669
+3% +$2.41K ﹤0.01% 2627
2020
Q4 		$63K Buy
22,519
+1,330
+6% +$3.88K ﹤0.01% 2446
2020
Q3 		$53K Sell
21,189
-1,138
-5% -$9.99K ﹤0.01% 2385
2020
Q2 		$303K Buy
22,327
+3,371
+18% +$34.9K ﹤0.01% 2171
2020
Q1 		$144K Sell
18,956
-11,155
-37% -$86.8K ﹤0.01% 2233
2019
Q4 		$190K Buy
30,111
+10,163
+51% +$48.3K ﹤0.01% 2322
2019
Q3 		$78K Buy
+19,948
New +$85.5K ﹤0.01% 2518

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Victory Capital Management's AKBA Position: Q2 2026 in Review

Victory Capital Management reduced its Akebia Therapeutics (AKBA) stake by 77% in Q2 2026, selling an estimated $118K and leaving 30,170 shares worth $34.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2417.

Victory Capital Management first reported a position in AKBA in Q3 2019 and has held it in 28 quarters since. The position peaked at $861K in Q3 2023. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Victory Capital Management held 30,170 shares of Akebia Therapeutics worth $34.4K as of Q2 2026.
  • Victory Capital Management sold 99,000 Akebia Therapeutics shares in Q2 2026, an estimated $118K.
  • Akebia Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2417 holding.
  • Victory Capital Management first reported a position in Akebia Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Victory Capital Management's Akebia Therapeutics position peaked at $861K in Q3 2023.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.